NEW YORK (GenomeWeb) – OpGen announced today that it has partnered with Beth Israel Deaconess Medical Center (BIDMC) on a verification study for OpGen's Acuitas AMR Gene Panel u5.47 Assay and the Acuitas Lighthouse Knowledgebase. The study will be among the first to examine potential diagnostic and antibiotic decision-making improvements that may be possible using rapid molecular testing and bioinformatics.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oct
02

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
10

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.